According to Humphrey and colleagues, one-third of patients with intravenous insulin-dextrose
(IDex) for hyperkalemia needed repeated treatments with IDex [
[1]
]. Besides, approximately 20% of patients who underwent IDex developed hypoglycemia
with a serum glucose level <4 mmol/L. Thus, the authors concluded that physicians
should monitor serum glucose levels after IDex treatment. This study focused on the
sequential changes in serum potassium and glucose levels and seemed helpful in actual
clinical settings. However, I would like to raise one issue that would have potentially
affected the results of this study: emergency hyperkalemia treatments other than IDex.Keywords
Abbreviation:
IDex (insulin-dextrose)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Clinical outcomes associated with the emergency treatment of hyperkalaemia with intravenous insulin-dextrose.Eur J Intern Med. 2022; 95: 87-92
- Diagnosis and treatment of hyperkalemia.Clevel Clin J Med. 2017; 84: 934-942
- Management of hyperkalemia: an update for the internist.Am J Med. 2015; 128: 1281-1287
Article info
Publication history
Published online: February 07, 2022
Accepted:
January 28,
2022
Received:
January 24,
2022
Identification
Copyright
© 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
